June 28, 2019

Halo Labs Inc (NEO:HALO) Global Cannabis Extraction Strategy and Timeline

Midas Letter
Midas Letter
Halo Labs Inc (NEO:HALO) Global Cannabis Extraction Strategy and Timeline

Halo Labs Inc (NEO:HALO) (OTCMKTS:AGEEF (FRA:A9KNis a company focused on extraction, creating quality cannabis oils and concentrates.  CEO Kiran Sidhu shares their intention to expand globally with an African (Lesotho) production and extraction strategy, with European distribution potential.  This is part of a long-term strategy to have the ability to compete directly with countries like India and China that traditionally have low-cost production and manufacturing abilities.  Mr. Sidhu shares his timeline for their strategy and looks ahead to profitability.  He also shares his thoughts on the global cannabis demand including the often overlooked African interest in cannabis.


Midas Letter
Midas Letter
Halo Labs Inc (NEO:HALO) Global Cannabis Extraction Strategy and Timeline

[stock_chart symbol=”HALO”]



JAMES WEST:    Kiran Sidhu joins me now. He’s the CEO of Halo Labs. Kiran, welcome.

KIRAN SIDHU:   Thanks for having me.

JAMES WEST:    Great to see you in London: big excitement going on with this Cannabis Europa event. Tell me about how Halo Labs is approaching the new market in the United Kingdom.

KIRAN SIDHU:   In terms of the United Kingdom and Europe, our strategy is a little different from others, and you know, being an oil and concentrate producer and having a very large bulk business, in particular in California, we believe that the way that we’re going to address Europe is actually through Lesotho in Africa.

JAMES WEST:    Okay, so Lesotho is the kingdom surrounded by South Africa, and you’ve made a partnership with them?

KIRAN SIDHU:   Correct. So we’ve done a little bit more than that, where the largest license in Lesotho is held by Bophelo Biosciences. And what we’ve done is, we’ve entered into a letter of intent to acquire 100 percent of Bophelo. So we are fully committed to the African strategy. So we will have, over the next year, five hectares of cultivation, and we’ll have 100,000, hopefully 100,000 square foot extraction facility in order to provide bulk biomass and bulk distillate to the European manufacturers.

JAMES WEST:    And so how much production do you anticipate from five hectares?

KIRAN SIDHU:   Oh, it will be – but keep in mind that, and again, what happened in the United States, and what I think will happen in Canada, will also happen in Europe, where now the United States, over 60 to 65 percent of all cannabis consumed, be it in an edible form or a topical form, is consumed in an oil and concentrate.

So the biomass ratio is somewhere between 12 to 1, so on five hectares, we’ll probably be producing around, in tonnage, probably about 10 tonnes a year, but that would only entail making less than a tonne of oil.

JAMES WEST:    Right. So is that a footprint that you envision expanding?

KIRAN SIDHU:   Yes, yes. And as we announced in Oregon, where we’re putting up now a CBD facility, we’ll be putting up also CBD production, we’ll be putting up specific hemp production, because our license allows us to go up to 200 hectares.

JAMES WEST:    Wow, that’s great.

KIRAN SIDHU:   And I don’t – I have, you know, we as a company sort of literally scoured the earth on Google maps and tried to come up with where’s an ideal place where you have favourable regulatory environment and favourable labour, favourable sun and soil, and Lesotho, to us, is ideal. And our, the company we’re in, is excellent. Aphria is there, Supreme is there, Canopy is there…so as far as publicly traded Canadian companies, we’re the fourth, but we find ourselves in excellent company.

JAMES WEST:    Sure. Do the laws in the United Kingdom and separately, Europe, permit the importation of CBD and THC in concentrated extracted format?

KIRAN SIDHU:   That’s a little bit more of a complicated question. So for those countries like Germany, like Denmark, like Holland right now, Bedrocan also is putting a very large facility in Lesotho. Those countries allow it, provided that the raw biomass is grown under good agricultural practices by their definition, and the oil is made under European Good Manufacturing Practice. And the understanding that we have is that the highest standards are the European standards.

So with those standards, when Canada permits imports, Australia we know is permitting imports, you can actually go into those markets as well.

JAMES WEST:    Okay, fantastic. So then, what about, will you use Lesotho feedstock to supply any of your US operations?

KIRAN SIDHU:   We can’t do that, because the US is ring-fenced, right?

JAMES WEST:    Right.

KIRAN SIDHU:   Right? Every state within the US is ring fenced.

JAMES WEST:    Right.

KIRAN SIDHU:   But inevitably, as we saw just recently, the House of Representatives has passed a bill last night, and things may be turning in the US. But again, that’s what’s so beautiful about Lesotho, because we can produce high quality at a low cost that, be it the Chinese, be it the Indians, be it whoever else comes in, we’ll be able to compete with them toe-to-toe.

JAMES WEST:    Interesting. Do you think that there will be resistance to using imported CBD and THC feedstock to governments that are seeking to capture the economic opportunity?

KIRAN SIDHU:   Again, very well poised, because Lesotho is a poor country. And so they have treaties under OCED and under UN auspices that permit them tariff exemptions. So for instance, in the US, textiles that are imported from Lesotho are exempt from tariffs that we keep hearing about in the US. So that was another reason that Lesotho was very favourable to us, because if tariffs do come down, they will be harder to implement against a country like Lesotho that, by nature, has that OCED protection.

JAMES WEST:    Sure. At what point in the timeline do you envision generating revenue from your operations in Lesotho?

KIRAN SIDHU:   We are hoping as early as Q2 of next year. Remember, we’re in the southern hemisphere, so the cycle is different; so the prime summer cycle, we’re using greenhouses. The prime summer cycle starts in November, so we’re hoping to put our first crop in the ground in November. And in terms of what we call offtake or demand, at this conference, I mean, there’s so many people who are in desperate need of biomass to make medicinal oil in Europe, that there’s no lack of demand. It’s an execution, not opportunity, and what we’ve proven in Oregon, what we’ve proven in Nevada, and what we’ve definitely proven in California, is that we can execute, we can execute quickly, and Lesotho to us is no different.

We’ve had a team on the ground for six months now, and we’re highly confident that we’ll have our first crop out by Q2 of next year.

JAMES WEST:    Okay, then, so in terms of what’s happening right now in the United Kingdom in this early stage of medical cannabis legalization, do you see the medical market moving forward fast enough that it’s going to be able to uptake all of your biomass that you can produce?

KIRAN SIDHU:   Well, not the United Kingdom, because the United Kingdom is lagging. But as I emphasized before, Germany, Holland, Italy, France, Malta, these are jurisdictions where now it’s becoming more prevalent. Now Greece is coming on strong.

So the prediction is that by 2023, and I think it was Prohibitions Partners report, that European demand will exceed North American demand. And the other thing that people don’t understand is Africa: it has significant demand. So New Frontier Data published reports last week on the African demand, and a lot of people, with the exception of Aurora, have forgotten the fact that South Africa has 60 million people. They have a culture that’s predisposed to cannabis, and they just decriminalized cannabis. And when I was in Johannesburg recently, and Capetown, consumption cafes are popping up in the collective model of California in the early days.

JAMES WEST:    Wow. So that’s a huge, huge market.

KIRAN SIDHU:   It’s a huge opportunity, and Lesotho is part of that common trade zone.

JAMES WEST:    Interesting. So how is this affecting your outlook on your revenue going out the next 12, 24 months?

KIRAN SIDHU:   In, I would say that this year we still hold firm to our 48 million number, with positive EBITDA hopefully by the fourth quarter. I always get asked by investors, How are you doing? Because our growth is at 300 percent quarter-over-quarter, you know, year-over-year. And you know, they keep asking to me, Are we going to sustain it? I’m not going to comment on the quarters; all I’m going to say is that going into Q3, at the end of June, our numbers are right where we expect them to be internally.

JAMES WEST:    Okay, great. Let’s leave it there, Kiran; we’ll come back to you soon. Thanks for joining me again.

KIRAN SIDHU:   Thanks, thanks for having me again.

Notice for Forward-Looking Information
Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Such forward-looking information includes that HALO Labs Inc will be a big, successful company in the cannabis sector; that cannabis use and sales will grow and HALO’s sales along with it; HALO’s intended acquisition of various foreign companies and expansion into the US market; that extraction is and will continue to be a fast growing and profitable sector of the cannabis industry; that HALO will reach $48M in revenues in 2019; HALO’s plans to produce concentrates and sell them in various locations throughout the world; that HALO could be granted licenses to expand; and that it will be able to carry out its business plans.
Readers are cautioned to not place undue reliance on forward-looking information. Forward looking information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on HALO. Such risks and uncertainties include, among other things: that a regulatory approval that may be required for the intended acquisitions and subsequent sales are not obtained or are obtained subject to conditions that are not anticipated; growing competition for intended acquisitions in the cannabis industry; potential future competition in the markets HALO operates for sales; competitors may quickly enter the industry; general economic conditions in the US, Canada and globally; the inability to secure financing necessary to carry out its business plans; competition for, among other things, capital and skilled personnel; the possibility that government policies or laws may not permit legal cannabis sales or growth or that favorable laws in place may change; HALO not adequately protecting its intellectual property; interruption or failure of information technology systems; the cannabis market may not grow as expected; HALO’s technology may not achieve the expected results and its accomplishments may be limited; even if it is granted patents, it may not have success at licensing its technologies or sell its products at the rate expected; planned acquisitions and partnerships may not materialize because of inability to agree on terms with prospective partners or targets; HALO’s business plan also carries risk, including its ability to comply with all applicable governmental regulations in a highly regulated business; incubator risk investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US federal and foreign laws; and other regulatory risks relating to HALO’s business, financings and strategic acquisitions, including securities laws, trade rules, and foreign country regulation that is not the same as Canadian or US regulations.
PAID ADVERTISEMENT.This communication is a paid advertisement and is not a recommendation to buy or sell securities. James West, Global Financial Network Ltd. and Midas Letter Media Corp. and their owners, managers, employees, and assigns (collectively “the Company”) has been paid by the profiled company or a third party to disseminate this communication. In this case the Company has been paid by HALO $300,000 US dollars for an article and video campaign and certain banner ads, and a budget of $450,000 is in place to place newsletters in social and other media.
This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. We have been compensated by HALO to conduct investor awareness advertising and marketing for HALO. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the profiled company. The profiled company or its affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our newsletters experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public and non-public sources but is not researched or verified in any way whatsoever to ensure the information is correct.
SHARE OWNERSHIP. The Company, which includes the owner and publisher of the Midas Letter may own shares and/or stock options of this featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Company will not notify the market when it decides to buy or sell shares of this profiled company in the market. The Company may be buying and selling additional shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
NOT AN INVESTMENT ADVISOR.The Company and its affiliates are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.
INDEMNIFICATION/RELEASE OF LIABILITY.By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing the Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
RISK OF INVESTING.Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don’t trade with money you can’t afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities.


Related Articles


Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.